Product fact sheet
DaVinci Arabinogalactan Powder: Larch Fiber Dose & Human Evidence
DaVinci Arabinogalactan Powder provides 4.25 g larch arabinogalactan per scoop; the cited microbiome trial used 15 g/day of a different branded larch ingredient.
The NIH label record lists 5 g larch extract yielding 4.25 g arabinogalactans per scoop. The strongest modern microbiome RCT cited here used 15 g/day of the branded ResistAid ingredient rather than this DaVinci finished product.
Adults comparing a gram-dose larch arabinogalactan powder rather than a small immune-support capsule, People interested in arabinogalactan microbiome research who understand the branded-ingredient mismatch
Anyone expecting one 4.25 g arabinogalactan serving to reproduce a 15 g/day ResistAid microbiome trial, Anyone treating a vaccine-antibody endpoint as proof of fewer infections or better digestive symptoms
Key tradeoff: The label states the arabinogalactan amount clearly, but published ResistAid trials are not exact DaVinci finished-product trials.
This is a factual fit-and-tradeoff summary, not a product recommendation. Formula, device and brand claims remain manufacturer claims unless the cited source is explicitly regulatory or independent testing.
DaVinci Laboratories Arabinogalactan Powder is a useful comparator because its label actually quantifies the relevant carbohydrate. The NIH Dietary Supplement Label Database records 5 g larch extract per scoop, yielding 4.25 g arabinogalactans, with 4 g dietary fiber.
That is much more decision-useful than an immune capsule containing only a few hundred milligrams of larch arabinogalactan.
What the microbiome trial used
A randomized, double-blind, placebo-controlled crossover trial in healthy adults tested 15 g/day of ResistAid larch arabinogalactan for six weeks.
The intervention changed aspects of fecal microbiome composition, with a tendency toward increased Bifidobacterium. But bowel habits, stool consistency and gastrointestinal symptoms did not significantly improve.
That gives us two important boundaries:
- the strongest endpoint was microbiome composition rather than digestive symptom relief; and
- the trial used 15 g/day of a branded ingredient, not one 4.25 g serving of this DaVinci product.
Immune evidence is a different endpoint
A separate randomized trial studied 1.5 and 4.5 g/day ResistAid around vaccination and measured immune-response endpoints. The higher dose is numerically close to DaVinci’s 4.25 g arabinogalactan serving, but similarity in grams does not make the products interchangeable.
The trial tested a specific branded larch ingredient and an immune endpoint—not this retail powder and not constipation or IBS symptoms.
Current label snapshot
| Feature | Specification |
|---|---|
| Botanical source | Larch tree (Larix laricina) extract |
| Larch extract | 5 g per scoop |
| Arabinogalactans | 4.25 g per scoop |
| Dietary fiber | 4 g |
| Other ingredients | None listed in the NIH label record |
How this differs from acacia
Larch arabinogalactan and gum acacia are both complex plant polysaccharides, but they should not be treated as identical fibers. The NOW Acacia Fiber comparator has randomized IBS-C stool-frequency evidence at 10 g/day, while the modern larch-arabinogalactan trial discussed here focused mainly on microbiome composition at 15 g/day.
For comparison, “arabinogalactan” alone is not enough. Source, dose, branded ingredient and endpoint all matter.
See the prebiotic substrate guide for the full comparison.
Formula facts
Ingredients, actives and label details
- Prebiotic substrate
- Larch tree (Larix laricina) extract yielding 85% arabinogalactans Basis: Manufacturer Source: Arabinogalactan Powder — Supplement Facts label record
- Arabinogalactan amount
- 5 g larch extract per scoop, yielding 4.25 g arabinogalactans Basis: Manufacturer Source: Arabinogalactan Powder — Supplement Facts label record
- Dietary fiber
- 4 g per scoop Basis: Manufacturer Source: Arabinogalactan Powder — Supplement Facts label record
- Microbiome evidence
- A randomized crossover trial used 15 g/day ResistAid for 6 weeks and changed fecal microbiome composition; Bifidobacterium showed a tendency to increase, while bowel habit and GI symptoms did not significantly change Basis: Randomized trial Source: Effect of arabinogalactan on the gut microbiome: a randomized, double-blind, placebo-controlled, crossover trial in healthy adults
- Immune endpoint evidence
- A separate randomized trial tested 1.5 and 4.5 g/day ResistAid around vaccination; this is immune-response evidence for a branded ingredient, not proof of digestive benefit for the DaVinci product Basis: Randomized trial Source: Immunomodulatory effects of ResistAid: a randomized, double-blind, placebo-controlled, multidose study
Source labels preserve provenance. Manufacturer specifications, ingredient lists and performance claims are not treated as independent clinical evidence; regulatory records and independent measurements are identified separately when available.
Safety first
What should make you slow down?
Use the product as directed, avoid treating concentrated wellness products as automatically harmless, and ask a qualified clinician when your situation or medication use makes the decision less routine.
Where to buy
Current tracked merchants
Commerce note: merchant economics never enter our editorial score. Affiliate links are identified as (paid link) and use sponsored-link markup.
No merchant destination is currently tracked for this product.
Source trail
Primary documents and supporting evidence
- Arabinogalactan Powder — current product listingDaVinci Laboratories · Manufacturer · retrieved 2026-08-12
- Arabinogalactan Powder — Supplement Facts label recordNIH Office of Dietary Supplements Dietary Supplement Label Database · Government health · retrieved 2026-08-12
- Effect of arabinogalactan on the gut microbiome: a randomized, double-blind, placebo-controlled, crossover trial in healthy adultsNutrition · Professional health · retrieved 2026-08-12
- Immunomodulatory effects of ResistAid: a randomized, double-blind, placebo-controlled, multidose studyJournal of the American College of Nutrition · Professional health · retrieved 2026-08-12